In individuals at increased risk of CRC, FIT has shown high sensitivity for CRC—particularly with thresholds ≤20 μg Hb/g feces—as well as for advanced adenomas on thresholds ≤4 μg Hb/g feces (14–16). Here, GSTM1 is linked to colorectal carcinoma.